Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
2013 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 34, no 3, 177-183 p.Article in journal (Refereed) Published
Patients with atrial fibrillation have a significantly increased risk of thromboembolic events such as ischaemic stroke, and patients are therefore recommended to be treated with anticoagulation treatment. The most commonly used anticoagulant consists of vitamin K antagonist such as warfarin. A new oral anticoagulation treatment, dabigatran, has recently been approved for stroke prevention among patients with atrial fibrillation. The purpose of this study was to estimate the cost-effectiveness of dabigatran as preventive treatment of stroke and thromboembolic events compared with warfarin in 65-year-old patients with atrial fibrillation in Sweden. less thanbrgreater than less thanbrgreater thanA decision analytic simulation model was used to estimate the long-term (20-year) costs and effects of the different treatments. The outcome measures are the number of strokes prevented, life years gained, and quality-adjusted life years (QALYs) gained. Costs and effect data are adjusted to a Swedish setting. Patients below 80 years of age are assumed to start with dabigatran 150 mg twice a day and switch to 110 mg twice a day at the age of 80 years due to higher bleeding risk. The price of dabigatran in Sweden is Euro2.82 (Swedish kronor 25.39) per day for both doses. The cost per QALY gained for dabigatran compared with warfarin is estimated at Euro7742, increasing to Euro12 449 if dabigatran is compared with only well-controlled warfarin treatment. less thanbrgreater than less thanbrgreater thanDabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit.
Place, publisher, year, edition, pages
Oxford University Press (OUP): Policy B , 2013. Vol. 34, no 3, 177-183 p.
Cost-effectiveness, Atrial fibrillation, Anticoagulants, Stroke
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-89523DOI: 10.1093/eurheartj/ehs157ISI: 000313831000008OAI: oai:DiVA.org:liu-89523DiVA: diva2:608234
Funding Agencies|Boehringer Ingelheim||County council of Ostergotland, Sweden||Bayer||Bristol-Myers Squibb||Pfizer||2013-02-262013-02-262013-09-11